BioCryst Pharmaceuticals (NASDAQ:BCRX) Announces Quarterly Earnings Results

BioCryst Pharmaceuticals (NASDAQ:BCRX) announced its quarterly earnings results on Monday. The biotechnology company reported ($0.07) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.07), Briefing.com reports. The firm had revenue of $117.10 million during the quarter, compared to analysts’ expectations of $113.99 million. During the same quarter in the prior year, the business earned ($0.19) EPS. The company’s quarterly revenue was up 35.1% compared to the same quarter last year.

BioCryst Pharmaceuticals Price Performance

NASDAQ BCRX traded down $0.10 on Tuesday, reaching $7.25. The company had a trading volume of 1,490,645 shares, compared to its average volume of 2,966,979. The firm has a market capitalization of $1.50 billion, a PE ratio of -11.87 and a beta of 1.89. The firm has a 50-day moving average of $7.84 and a 200-day moving average of $6.95. BioCryst Pharmaceuticals has a 1 year low of $4.03 and a 1 year high of $8.88.

Wall Street Analyst Weigh In

BCRX has been the subject of several recent research reports. StockNews.com upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, August 6th. Needham & Company LLC reissued a “buy” rating and set a $14.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday. JMP Securities upped their target price on BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 6th. HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 6th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, BioCryst Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $14.67.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.